SIHUAN PHARM(00460.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 224.7 million, YoY increase of 119%

NewTimeSpace News: August 26, 2026, SIHUAN PHARM(00460.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 1.16 billion, increased by 1.31% YoY; Net Profit stood at CNY 212.58 million, YoY increase of 221.15%; Profit Attributable to Shareholders stood at CNY 224.7 million, YoY increase of 119%; Basic Earnings Per Share (EPS) stood at CNY cents 2.49.

In terms of profitability, SIHUAN PHARM Gross Profit changed from CNY 757.26 million in the same period last year to CNY 681.66 million in the current period, decreased by CNY 75.6 million; gross profit margin changed from 66.07% in the same period last year to 58.7% in the current period, decreased by 7.36 percentage points; net profit changed from CNY 66.19 million in the same period last year to CNY 212.58 million in the current period, increased by CNY 146.39 million; net profit margin changed from 5.78% in the same period last year to 18.31% in the current period, increased by 12.53 percentage points. 

In terms of earnings quality, SIHUAN PHARM Operating Profit changed from CNY 264.38 million in the same period last year to CNY 313.47 million in the current period, increased by CNY 49.09 million; Operating Profit Margin changed from 23.07% in the same period last year to 26.99% in the current period, increased by 3.93 percentage points. 

In terms of financial soundness, SIHUAN PHARM Debt-to-Asset Ratio changed from 53.48% in the same period last year to 40.17% in the current period, decreased by 13.31 percentage points; Total Equity changed from CNY 4.941 billion in the same period last year to CNY 6.962 billion in the current period, increased by CNY 2.02 billion; Current Liabilities changed from CNY 3.33 billion in the same period last year to CNY 3.69 billion in the current period, increased by CNY 367.26 million; Quick Ratio changed from 1.61 in the same period last year to 1.65 in the current period, increased by 0.04 percentage points. 

In terms of R&D investment focus, SIHUAN PHARM R&D Expenses changed from CNY 152.85 million in the same period last year to CNY 105.59 million in the current period, decreased by CNY 47.26 million; R&D to Total Revenue Ratio changed from 13.33% in the same period last year to 9.09% in the current period, decreased by 4.24 percentage points. 

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.